Asset Details
Do you wish to reserve the book?
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
Do you wish to request the book?
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
2017
Overview
A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red blood cells by expressing chimeric proteins of VHHs with Glycophorin A or Kell. Mice whose red blood cells carry the chimeric proteins exhibit resistance to 10,000 times the lethal dose (LD
50
) of BoNT/A, and transfusion of these red blood cells into naive mice affords protection for up to 28 days. We further utilize an improved CD34+ culture system to engineer human red blood cells that express these chimeric proteins. Mice transfused with these red blood cells are resistant to highly lethal doses of BoNT/A. We demonstrate that engineered red blood cells expressing VHHs can provide prolonged prophylactic protection against bacterial toxins without inducing inhibitory immune responses and illustrates the potentially broad translatability of our strategy for therapeutic applications.
The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers long lasting protection against a high dose of BoNT/A.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Animals
/ Antibodies, Neutralizing - administration & dosage
/ Antibodies, Neutralizing - genetics
/ Antibodies, Neutralizing - metabolism
/ Botulinum Toxins, Type A - metabolism
/ Botulinum Toxins, Type A - toxicity
/ Erythroid Precursor Cells - metabolism
/ Erythroid Precursor Cells - transplantation
/ Erythroid Precursor Cells - virology
/ Genetic Vectors - metabolism
/ Humanities and Social Sciences
/ Humans
/ Membrane Glycoproteins - genetics
/ Membrane Glycoproteins - metabolism
/ Metalloendopeptidases - genetics
/ Metalloendopeptidases - metabolism
/ Mice
/ Science
/ Single-Domain Antibodies - administration & dosage
/ Single-Domain Antibodies - genetics
/ Single-Domain Antibodies - metabolism
/ Toxins
